{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T23:22:14Z","timestamp":1793748134919,"version":"4.6.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T00:00:00Z","timestamp":1678924800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T00:00:00Z","timestamp":1678924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Capital Construction Funds within the provincial budget","award":["2020C038-1"],"award-info":[{"award-number":["2020C038-1"]}]},{"name":"Shanghai Zhimeng Biopharma, Inc"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hepatitis B virus (HBV) core protein-targeting antivirals (CpTAs) are promising therapeutic agents for treating chronic hepatitis B (CHB). In this study, the antiviral activity, pharmacokinetics (PK), and tolerability of ZM-H1505R (Canocapavir), a chemically unique HBV CpTA, were evaluated in patients with CHB.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study was a double-blind, randomized, placebo-controlled phase 1b trial in Chinese CHB patients. Noncirrhotic and treatment-naive CHB patients were divided into three cohorts (10 patients per cohort) and randomized within each cohort in a ratio of 4:1 to receive a single dose of 50, 100, or 200\u00a0mg of Canocapavir or placebo once a day for 28 consecutive days.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Canocapavir was well tolerated, with the majority of adverse reactions being grade I or II in severity. There were no serious adverse events, and no patients withdrew from the study. Corresponding to 50, 100, and 200\u00a0mg doses of Canocapavir, the mean plasma trough concentrations of the drug were 2.7-, 7.0-, and 14.6-fold of its protein-binding adjusted HBV DNA EC\n                      <jats:sub>50<\/jats:sub>\n                      (135\u00a0ng\/mL), respectively, with linear PK and a low-to-mild accumulation rate (1.26\u20131.99). After 28\u00a0days of treatment, the mean maximum HBV DNA declines from baseline were -1.54, -2.50, -2.75, and -0.47 log\n                      <jats:sub>10<\/jats:sub>\n                      IU\/mL for the 50, 100, and 200\u00a0mg of Canocapavir or placebo groups, respectively; and the mean maximum pregenomic RNA declines from baseline were -1.53, -2.35, -2.34, and -0.17 log\n                      <jats:sub>10<\/jats:sub>\n                      copies\/mL, respectively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Canocapavir treatment is tolerated with efficacious antiviral activity in CHB patients, supporting its further development in treating HBV infection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>ClinicalTrials.gov, number NCT05470829).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12916-023-02814-w","type":"journal-article","created":{"date-parts":[[2023,3,26]],"date-time":"2023-03-26T16:45:46Z","timestamp":1679849146000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Safety, tolerability, pharmacokinetics, and antiviral activity of the novel core protein allosteric modulator ZM-H1505R (Canocapavir) in chronic hepatitis B patients: a randomized multiple-dose escalation trial"],"prefix":"10.1186","volume":"21","author":[{"given":"Haiyan","family":"Jia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajia","family":"Mai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuiyun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingrui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengjiao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxue","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuhong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Hua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiyun","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruoling","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huanming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junqi","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhua","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,16]]},"reference":[{"issue":"10049","key":"2814_CR1","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/S0140-6736(16)30579-7","volume":"388","author":"JD Stanaway","year":"2016","unstructured":"Stanaway JD, Flaxman AD, Naghavi M, Fitzmaurice C, Vos T, Abubakar I, et al. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Lancet. 2016;388(10049):1081\u20138. https:\/\/doi.org\/10.1016\/S0140-6736(16)30579-7.","journal-title":"Lancet"},{"issue":"10003","key":"2814_CR2","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1016\/S0140-6736(15)61412-X","volume":"386","author":"A Schweitzer","year":"2015","unstructured":"Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015;386(10003):1546\u201355. https:\/\/doi.org\/10.1016\/S0140-6736(15)61412-X.","journal-title":"Lancet"},{"issue":"1","key":"2814_CR3","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1001\/jama.295.1.65","volume":"295","author":"CJ Chen","year":"2006","unstructured":"Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295(1):65\u201373. https:\/\/doi.org\/10.1001\/jama.295.1.65.","journal-title":"JAMA"},{"issue":"8","key":"2814_CR4","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1016\/j.cgh.2007.06.015","volume":"5","author":"UH Iloeje","year":"2007","unstructured":"Iloeje UH, Yang HI, Jen CL, Su J, Wang LY, You SL, et al. Risk and predictors of mortality associated with chronic hepatitis B infection. Clin Gastroenterol Hepatol. 2007;5(8):921\u201331. https:\/\/doi.org\/10.1016\/j.cgh.2007.06.015.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"2814_CR5","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1016\/j.jhep.2021.11.024","volume":"76","author":"G Wong","year":"2022","unstructured":"Wong G, Gane E, Lok A. How to achieve functional cure of HBV: Stopping NUCs, adding interferon or new drug development. J Hepatol. 2022;76(6):1249\u201362. https:\/\/doi.org\/10.1016\/j.jhep.2021.11.024.","journal-title":"J Hepatol"},{"issue":"1 Suppl","key":"2814_CR6","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.jhep.2016.02.016","volume":"64","author":"D Durantel","year":"2016","unstructured":"Durantel D, Zoulim F. New antiviral targets for innovative treatment concepts for hepatitis B virus and hepatitis delta virus. J Hepatol. 2016;64(1 Suppl):S117-117S131.","journal-title":"J Hepatol"},{"issue":"7","key":"2814_CR7","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1080\/13543784.2017.1333105","volume":"26","author":"V Soriano","year":"2017","unstructured":"Soriano V, Barreiro P, Benitez L, Pe\u00f1a JM, de Mendoza C. New antivirals for the treatment of chronic hepatitis B. Expert Opin Investig Drugs. 2017;26(7):843\u201351. https:\/\/doi.org\/10.1080\/13543784.2017.1333105.","journal-title":"Expert Opin Investig Drugs"},{"issue":"7","key":"2814_CR8","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1111\/jphp.12916","volume":"70","author":"H Zhang","year":"2018","unstructured":"Zhang H, Zhu X, Li Q, Lou J, Sun J, Shen Z, et al. Clinical evaluation of efficacy, tolerability and pharmacokinetics of yimitasvir phosphate in patients infected with hepatitis C virus. J Pharm Pharmacol. 2018;70(7):855\u201364. https:\/\/doi.org\/10.1111\/jphp.12916.","journal-title":"J Pharm Pharmacol"},{"issue":"2","key":"2814_CR9","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1093\/cid\/ciaa961","volume":"73","author":"H Zhang","year":"2021","unstructured":"Zhang H, Wang F, Zhu X, Chen Y, Chen H, Li X, et al. Antiviral activity and pharmacokinetics of the Hepatitis B Virus (HBV) capsid assembly modulator gls4 in patients with chronic HBV infection. Clin Infect Dis. 2021;73(2):175\u201382. https:\/\/doi.org\/10.1093\/cid\/ciaa961.","journal-title":"Clin Infect Dis"},{"issue":"12","key":"2814_CR10","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1080\/14728222.2017.1397134","volume":"21","author":"LY Mak","year":"2017","unstructured":"Mak LY, Wong DK, Seto WK, Lai CL, Yuen MF. Hepatitis B core protein as a therapeutic target. Expert Opin Ther Targets. 2017;21(12):1153\u20139. https:\/\/doi.org\/10.1080\/14728222.2017.1397134.","journal-title":"Expert Opin Ther Targets"},{"issue":"2","key":"2814_CR11","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1053\/j.gastro.2020.04.036","volume":"159","author":"F Zoulim","year":"2020","unstructured":"Zoulim F, Lenz O, Vandenbossche JJ, Talloen W, Verbinnen T, Moscalu I, et al. JNJ-56136379, an HBV capsid assembly modulator, is well-tolerated and has antiviral activity in a phase 1 study of patients with chronic infection. Gastroenterology. 2020;159(2):521-33.e9. https:\/\/doi.org\/10.1053\/j.gastro.2020.04.036.","journal-title":"Gastroenterology"},{"issue":"2","key":"2814_CR12","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/S2468-1253(19)30346-2","volume":"5","author":"MF Yuen","year":"2020","unstructured":"Yuen MF, Agarwal K, Gane EJ, Schwabe C, Ahn SH, Kim DJ, et al. Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial. Lancet Gastroenterol Hepatol. 2020;5(2):152\u201366. https:\/\/doi.org\/10.1016\/S2468-1253(19)30346-2.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"12","key":"2814_CR13","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1038\/s41575-022-00700-z","volume":"19","author":"F Zoulim","year":"2022","unstructured":"Zoulim F, Zlotnick A, Buchholz S, Donaldson E, Fry J, Gaggar A, et al. Nomenclature of HBV core protein-targeting antivirals. Nat Rev Gastroenterol Hepatol. 2022;19(12):748\u201350. https:\/\/doi.org\/10.1038\/s41575-022-00700-z.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2814_CR14","doi-asserted-by":"publisher","first-page":"104557","DOI":"10.1016\/j.antiviral.2019.104557","volume":"169","author":"V Rat","year":"2019","unstructured":"Rat V, Seigneuret F, Burlaud-Gaillard J, Lemoine R, Hourioux C, Zoulim F, et al. BAY 41\u20134109-mediated aggregation of assembled and misassembled HBV capsids in cells revealed by electron microscopy. Antiviral Res. 2019;169:104557.","journal-title":"Antiviral Res"},{"key":"2814_CR15","doi-asserted-by":"publisher","first-page":"42374","DOI":"10.1038\/srep42374","volume":"7","author":"Z Zhou","year":"2017","unstructured":"Zhou Z, Hu T, Zhou X, Wildum S, Garcia-Alcalde F, Xu Z, et al. Heteroaryldihydropyrimidine (HAP) and Sulfamoylbenzamide (SBA) Inhibit Hepatitis B Virus replication by different molecular mechanisms. Sci Rep. 2017;7:42374. https:\/\/doi.org\/10.1038\/srep42374.","journal-title":"Sci Rep"},{"key":"2814_CR16","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.antiviral.2018.07.011","volume":"158","author":"A Corcuera","year":"2018","unstructured":"Corcuera A, Stolle K, Hillmer S, Seitz S, Lee JY, Bartenschlager R, et al. Novel non-heteroarylpyrimidine (HAP) capsid assembly modifiers have a different mode of action from HAPs in vitro. Antiviral Res. 2018;158:135\u201342. https:\/\/doi.org\/10.1016\/j.antiviral.2018.07.011.","journal-title":"Antiviral Res"},{"issue":"11","key":"2814_CR17","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1038\/s41573-019-0037-0","volume":"18","author":"GC Fanning","year":"2019","unstructured":"Fanning GC, Zoulim F, Hou J, Bertoletti A. Therapeutic strategies for hepatitis B virus infection: towards a cure. Nat Rev Drug Discov. 2019;18(11):827\u201344. https:\/\/doi.org\/10.1038\/s41573-019-0037-0.","journal-title":"Nat Rev Drug Discov"},{"key":"2814_CR18","first-page":"274A","volume":"68","author":"ZJ Zhang","year":"2018","unstructured":"Zhang ZJ, Liang B, Lu YY, Chen HM. A novel HBV capsid formation inhibitor that additively inhibits virus replication in combination with tenofovir or IFN-alpha. Hepatology. 2018;68:274A.","journal-title":"Hepatology"},{"key":"2814_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.gastha.2023.01.001","author":"X Jiang","year":"2023","unstructured":"Jiang X, Hua B, Liu G, Xia T, Deng A, Lu H, et al. Safety, tolerability, and pharmacokinetics of a novel HBV capsid assembly modulator. Gastro Hep Advances. 2023. https:\/\/doi.org\/10.1016\/j.gastha.2023.01.001.","journal-title":"Gastro Hep Advances"},{"issue":"5","key":"2814_CR20","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1053\/j.gastro.2018.12.023","volume":"156","author":"MF Yuen","year":"2019","unstructured":"Yuen MF, Gane EJ, Kim DJ, Weilert F, Yuen Chan HL, Lalezari J, et al. Antiviral Activity, safety, and pharmacokinetics of capsid assembly modulator NVR 3\u2013778 in patients with Chronic HBV infection. Gastroenterology. 2019;156(5):1392-403.e7. https:\/\/doi.org\/10.1053\/j.gastro.2018.12.023.","journal-title":"Gastroenterology"},{"key":"2814_CR21","doi-asserted-by":"publisher","first-page":"143026","DOI":"10.1155\/2010\/143026","volume":"2010","author":"Y Jiang","year":"2010","unstructured":"Jiang Y, Ma Z, Xin G, Yan H, Li W, Xu H, et al. Th1 and Th2 immune response in chronic hepatitis B patients during a long-term treatment with adefovir dipivoxil. Mediators Inflamm. 2010;2010:143026.","journal-title":"Mediators Inflamm"},{"issue":"5608","key":"2814_CR22","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1126\/science.1077215","volume":"299","author":"K Deres","year":"2003","unstructured":"Deres K, Schr\u00f6der CH, Paessens A, Goldmann S, Hacker HJ, Weber O, et al. Inhibition of hepatitis B virus replication by drug-induced depletion of nucleocapsids. Science. 2003;299(5608):893\u20136. https:\/\/doi.org\/10.1126\/science.1077215.","journal-title":"Science"},{"issue":"1","key":"2814_CR23","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/j.1365-2893.2008.01037.x","volume":"16","author":"HL Chan","year":"2009","unstructured":"Chan HL, Wong GL, Choi PC, Chan AW, Chim AM, Yiu KK, et al. Alanine aminotransferase-based algorithms of liver stiffness measurement by transient elastography (Fibroscan) for liver fibrosis in chronic hepatitis B. J Viral Hepat. 2009;16(1):36\u201344. https:\/\/doi.org\/10.1111\/j.1365-2893.2008.01037.x.","journal-title":"J Viral Hepat"},{"issue":"6","key":"2814_CR24","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1111\/apt.14497","volume":"47","author":"GL Wong","year":"2018","unstructured":"Wong GL, Seto WK, Wong VW, Yuen MF, Chan HL. Review article: long-term safety of oral anti-viral treatment for chronic hepatitis B. Aliment Pharmacol Ther. 2018;47(6):730\u20137. https:\/\/doi.org\/10.1111\/apt.14497.","journal-title":"Aliment Pharmacol Ther"},{"issue":"Suppl 1","key":"2814_CR25","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1111\/liv.13304","volume":"37","author":"EJ Gane","year":"2017","unstructured":"Gane EJ. Future anti-HBV strategies. Liver Int. 2017;37(Suppl 1):40\u20134. https:\/\/doi.org\/10.1111\/liv.13304.","journal-title":"Liver Int"},{"issue":"2","key":"2814_CR26","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.antiviral.2011.08.012","volume":"92","author":"G Billioud","year":"2011","unstructured":"Billioud G, Pichoud C, Puerstinger G, Neyts J, Zoulim F. The main hepatitis B virus (HBV) mutants resistant to nucleoside analogs are susceptible in vitro to non-nucleoside inhibitors of HBV replication. Antiviral Res. 2011;92(2):271\u20136. https:\/\/doi.org\/10.1016\/j.antiviral.2011.08.012.","journal-title":"Antiviral Res"},{"issue":"1","key":"2814_CR27","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1080\/21505594.2022.2093444","volume":"13","author":"S Phillips","year":"2022","unstructured":"Phillips S, Jagatia R, Chokshi S. Novel therapeutic strategies for chronic hepatitis B. Virulence. 2022;13(1):1111\u201332. https:\/\/doi.org\/10.1080\/21505594.2022.2093444.","journal-title":"Virulence"},{"issue":"5","key":"2814_CR28","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1016\/j.jhep.2022.01.007","volume":"76","author":"MJ Sonneveld","year":"2022","unstructured":"Sonneveld MJ, Chiu SM, Park JY, Brakenhoff SM, Kaewdech A, Seto WK, et al. Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels. J Hepatol. 2022;76(5):1042\u201350. https:\/\/doi.org\/10.1016\/j.jhep.2022.01.007.","journal-title":"J Hepatol"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-023-02814-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-023-02814-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-023-02814-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,26]],"date-time":"2023-03-26T16:48:23Z","timestamp":1679849303000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-023-02814-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,16]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2814"],"URL":"https:\/\/doi.org\/10.1186\/s12916-023-02814-w","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,16]]},"assertion":[{"value":"28 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Institutional Review Board of the First Hospital of Jilin University, and conducted according to the Declaration of Helsinki, Guidelines for Good Clinical Practice, and local laws and regulations. The ethics approval number is 20Y201-006. All patients provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"XJ, BH, TX, GL, AD, BL, RG, HL, ZW, HC, and ZZ are employees of Shanghai Zhimeng Biopharma, which sponsored this study. The other authors declare no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"98"}}